<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143646</url>
  </required_header>
  <id_info>
    <org_study_id>BIHKF 3</org_study_id>
    <nct_id>NCT04143646</nct_id>
  </id_info>
  <brief_title>New Technologies for Intensive Prevention Programs - NET-IPP</brief_title>
  <acronym>NET-IPP</acronym>
  <official_title>New Technologies for Intensive Prevention Programs - NET-IPP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzzentrum Bremen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzzentrum Bremen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized trial patients hospitalized for myocardial infarction are prospectively
      enrolled and assigned to either a web-based intensive prevention program or usual care (1 : 1
      randomization). The web-based program includes telemetric transmission of data on
      cardiocascular risk factors (physical activity, blood pressure, body weight) by patients to
      the study center, e-learning modules by the study center and repetitive electronic contacts
      by e-mails and apps between a prevention assistant and the patient.

      In addition, genetic risk on cardiovascular events will be assessed in all patients of the
      intervention group by a polygenetic risk score (PRS). Patients of the intervention group are
      randomly assigned to disclosure of genetic risk vs. no disclosure. The study hypothesis is
      that disclosure of genetic risk improves cardiovascular risk factor control by increased
      patient motivation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participants with serious adverse cardiovascular events</measure>
    <time_frame>24 months</time_frame>
    <description>Serious adverse cardiovascular events are death (total and cardiovascular), resuscitations, strokes, myocardial infarctions, coronary revascularizations or hospitalizations due to unstable angina.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>24 months</time_frame>
    <description>LDL cholesterol levels in mg per dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking status</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of participants who are active smokers in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical inactivity</measure>
    <time_frame>24 months</time_frame>
    <description>Caloric expenditure as assessed by IPAQ (International Physical Activity Questionnaire) in kilocalories per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 months</time_frame>
    <description>Systolic and diastolic blood pressure measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>24 months</time_frame>
    <description>Body mass index in kg/mÂ² (calculated from body weight and height)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24 months</time_frame>
    <description>HbA1c levels in %</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adherence to preventive medication</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of patients with lipid-lowering medication, antiplatelets (= aspirine, ticagrelor, prasugrel, clopidogrel)</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Point score of the European Quality of Life 5 Dimensions (EQ5D) Questionnaire - Visual Analogue Scale (VAS). The Scale ranges from 0 to 100, with 100 indicating the best Quality of Life and 0 indicating the worst Quality of Life</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">864</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Web-based prevention program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts.
In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Web-based prevention program</intervention_name>
    <description>Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.
In a substudy evaluation of disclosure of genetic risk.</description>
    <arm_group_label>Web-based prevention program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalization due to acute myocardial infarction (ST-elevation or non-ST-elevation
             myocardial infarction) defined according to valid international guidelines

          2. Access to internet and consent to participate in a web-based prevention program

          3. Consent for genetic risk assessment for cardiovascular events and risk disclosure
             according to randomization

        Exclusion Criteria:

          1. Patient refusal or inability to give informed consent

          2. Hemodynamically significant valvular heart disease

          3. Exercise limitations due to clinical conditions not related to CAD (such as severe
             orthopedic disorders,..)

          4. Any major non-cardiac condition that would adversely affect survival during the
             duration of the study (such as cancer with prognosis &lt; 2 years,..)

          5. Inability to cooperate with the protocol, including longterm follow-up

          6. Chronic drug and alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Harm Wienbergen, M.D.</last_name>
    <phone>+49-421-879-1430</phone>
    <email>harm.wienbergen@klinikum-bremen-ldw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harm Wienbergen, M.D.</last_name>
      <phone>+49-421-879-1430</phone>
      <email>harm.wienbergen@klinikum-bremen-ldw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herzzentrum Bremen</investigator_affiliation>
    <investigator_full_name>Dr. Harm Wienbergen</investigator_full_name>
    <investigator_title>Head of the Bremen Institute for Heart and Circulation Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

